Announced details
Nonclinical in vivo distribution evaluation of cell therapy products; cancer immunocellular therapy
R² above 0.99; PCR amplification efficiency of 90%–110%; RE values within ±25%; CV values within 25% except for 1 case. LLOQ was 0.25 cells/mg of tissue weight in the liver, lungs, kidneys and heart; 1 cell/mg of tissue weight in the spleen and ovaries; and 0.3 cells/μL in blood.
Development partner for the eNK® cell therapy AKT-01/HLCN061. Akatsuki is leading development.
Head office: 8-1 Kakuda-cho, Kita-ku, Osaka; Representative Director: Yamazaki Junya (山﨑順也). A biotechnology company developing next-generation cellular immunotherapies for cancer and other serious diseases.
Kobe Research Institute (Kobe; affiliation of the paper's authors)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Peer-reviewed journal "Regenerative Therapy"; Manuscript Number: 33 (2026) 101189
| Item | Details |
|---|---|
| Names of Products / Services Covered | eNK® cells, HLCN061（AKT-01）, Direct qPCR method |
| Counterparty | Akatsuki Therapeutics |
| Counterparty overview | Head office: 8-1 Kakuda-cho, Kita-ku, Osaka; Representative Director: Yamazaki Junya (山﨑順也). A biotechnology company developing next-generation cellular immunotherapies for cancer and other serious diseases. |
| Relationship with the Company | Development partner for the eNK® cell therapy AKT-01/HLCN061. Akatsuki is leading development. |
| Applicable area | Nonclinical in vivo distribution evaluation of cell therapy products; cancer immunocellular therapy |
| Location | Kobe Research Institute (Kobe; affiliation of the paper's authors) |
| Quantitative Effects | R² above 0.99; PCR amplification efficiency of 90%–110%; RE values within ±25%; CV values within 25% except for 1 case. LLOQ was 0.25 cells/mg of tissue weight in the liver, lungs, kidneys and heart; 1 cell/mg of tissue weight in the spleen and ovaries; and 0.3 cells/μL in blood. |
| Source | Peer-reviewed journal "Regenerative Therapy"; Manuscript Number: 33 (2026) 101189 |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report research findings establishing an effective Direct qPCR method for quantitative evaluation in nonclinical in vivo distribution studies of eNK® cells.